DDInter713 DDInter1840
Febuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout who have an inadequate response or intolerance to [allopurinol]. Gout is a form of arthritis that is caused by the accumulation of uric acid crystal in or around a joint, leading to inflammation and further deposition of uric acid crystal deposition in bones, joints, tissues, and other organs in the long term. Gout is closely associated with hyperuricemia. Febuxostat works by inhibiting the activity of an enzyme that is responsible for the synthesis of uric acid, thereby reducing serum uric acid levels. In February 2019, a black box warning
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Febuxostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofarabine
Clofarabine {u} (Compound) causes {v} (Side Effect) Mediastinal disorder
Mediastinal disorder {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Febuxostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Theophylline {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Febuxostat {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Febuxostat {u} may lead to a major life threatening interaction when taken with {v} Mercaptopurine
Mercaptopurine {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Febuxostat may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Trabectedin (Compound)
Febuxostat may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)
Febuxostat may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)
Febuxostat may lead to a major life threatening interaction when taken with Mercaptopurine and Mercaptopurine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)